|1.||Shalinsky, D R: 1 article (01/2011)|
|2.||Boven, E: 1 article (01/2011)|
|3.||Brega, N: 1 article (01/2011)|
|4.||Lasch, P: 1 article (01/2011)|
|5.||Giaccone, G: 1 article (01/2011)|
|6.||Fiedler, W: 1 article (01/2011)|
|7.||Courtney, R: 1 article (01/2011)|
|8.||Abbattista, A: 1 article (01/2011)|
|9.||van der Horst, I: 1 article (01/2011)|
|10.||Bokemeyer, C: 1 article (01/2011)|
07/01/2006 - "In summary, SU14813 inhibited target RTK activity in vivo in association with reduction in angiogenesis, target RTK-mediated proliferation, and survival of tumor cells, leading to broad and potent antitumor efficacy. "
07/01/2006 - "In cellular assays, SU14813 inhibited ligand-dependent and ligand-independent proliferation, migration, and survival of endothelial cells and/or tumor cells expressing these targets. "
01/01/2011 - "this phase I, open-label, dose-escalation study investigated SU14813, an oral multitargeted tyrosine kinase inhibitor, in adults with solid tumors. "
07/01/2006 - "SU14813 inhibited VEGFR-2, PDGFR-beta, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent fashion. "
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|2.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|3.||Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)
|1.||Heterologous Transplantation (Xenotransplantation)